



09/167237

cgc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jan Zavada et al.

Group: 1600

Patent No.: 7,115,715

Group Art Unit: 1642

Issued : October 3, 2006

Examiner: J. Blanchard

For : Anti-Idiotypic Antibodies  
to MN Proteins and MN  
Polypeptides

**Certificate**

DEC 14 2006

**of Correction**

REQUEST FOR CERTIFICATE OF CORRECTION OF  
PATENT OFFICE'S MISTAKES (37 CFR Section 1.322)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attention: Certificate of Correction Branch

Sir:

Enclosed in duplicate is Form PTO-1050, with at least one copy being suitable for printing, indicating errors in the above-identified patent to be corrected. The Certificate of Correction is required to correct amendments that were requested to be made in the Preliminary Amendment filed in the U.S. Patent and Trademark Office (PTO) on September 21, 2001, the Amendment filed in the U.S. PTO on July 22, 2004 and the Submission of Substitute Sequence Listing submitted on November 15, 2005, which amendments were not made by the PTO.

Please correct the above-identified patent as follows:

Column 23,

Table 1, line 52, "Intron" should read -- Exon --

DEC 18 2006

Column 24,

line 19, "Rnase" should read - RNase --.

Columns 129 and 130

Consisting of a portion of the SEQUENCE LISTING containing  
SEQ ID NOS: 69-77 should be deleted and the attached new  
sheet containing SEQ ID NOS: 69-77 should be inserted  
therefor.

Columns 149 and 150

Consisting of a portion of the SEQUENCE LISTING containing  
SEQ ID NO: 116 should be deleted and the attached new sheet  
containing SEQ ID NO: 116 should be inserted therefor.

REMARKS

As explained in the Preliminary Amendment filed in the  
U.S. PTO on September 21, 2001, the Specification was asked to be  
amended in Table 1, Column 23, line 52 in order to replace  
"Intron" with "Exon". Column 23, lines 34-41 reads as follows:

Exon-Intron Structure of Complete MN Genomic  
Region

The complete sequence of the overlapping  
clones contains 10,898 bp (SEQ ID NO: 5).  
Figure 5 depicts the organization of the  
human MN gene, showing the location of all 11  
exons as well as the 2 upstream and 6  
intronic Alu repeat elements. All the exons  
are small, ranging from 27 to 191 bp, with  
the exception of the first exon which is 445  
bp. The intron sizes range from 89 to 1400  
bp.

DEC 18 2005

[Emphasis added.] As the above quote shows, the MN gene contains 11 exons, and that the first exon contains 445 base pairs. The top section of Table 1 depicts 11 regions wherein the first region contains 445 base pairs. Further, the same Table 1 can be found in parent the application, U.S. Patent 6,297,041. Table 1 (at column 21) of U.S. Patent No. 6,297,041 reads "Exon" on its fifth line. Applicants respectfully submit that the amendment at Table, 1, Column 23, line 52 of the instant patent corrects a typographical, proofreading error that would be obvious to those of skill in the art.

In addition the amendment to Column 24, line 19 was also requested to be made in the Preliminary Amendment dated September 21, 2001 to correct a typrographical/proofreading error.

As explained in the Amendment submitted to the PTO on July 22, 2004, the correction to Columns 129 and 130 is made so that SEQ ID NO: 76 in the SEQUENCE LISTING will be consistent with the correct sequence for SEQ ID NO: 76 seen in TABLE 1 of the Specification. As seen in TABLE 1 at column, line 61, the correct sequence for SEQ ID NO: 76 (the 5'splice donor for Exon 10) is CACAG GTATTA. The sequence ATACA GGGGAT is actually the correct sequence for SEQ ID NO: 77 (the 3' splice acceptor for Intro), as shown in TABLE 1 and SEQ ID NO: 77 in the SEQUENCE LISTING.

DEC 18 2005

As explained in the Submission of Substitute Sequence Listing filed in the PTO on November 15, 2005, SEQ ID NO: 116 was corrected at columns 149 and 150 so that it would be consistent with the correct sequence for SEQ ID NO: 116. As seen at column 53, line 40 of the Specification, the correct sequence for SEQ ID NO: 116 is (Gly<sub>4</sub>-Ser)<sub>3</sub>.

Note that the substitute computer readable copy (CRF) of the SEQUENCE LISTING submitted to the U.S. PTO on November 15, 2005 contains the correct sequences for SEQ ID NOS: 76 and 116.


Patentees respectfully point out that the aforementioned errors are "errors of consequence," and in accordance with the Manual of Patent Examining Procedure (MPEP) a corrected Certificate of Correction should be issued.

Since the omission of the amendments to the specification and SEQUENCE LISTING are due to a PTO error, no fees are required to be paid by the Patentees to issue the Certificate of Correction.

Please send the corrected Certificate of Correction to:

Leona L. Lauder  
235 Montgomery Street, Suite 1026  
San Francisco, CA 94104-3008.

Respectfully submitted,

  
Leona L. Lauder  
Attorney for Patentees  
Registration No. 30,863

Dated: December 7, 2006

DEC 18 2005

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 7,115,715 B2

DATED : October 3, 2006

INVENTOR(S) : Jan Zavada et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 23, Table 1,

Line 52, "Intron" should read -- Exon --.

Column 24,

Line 19, "Rnase" should read -- RNase --.

Columns 129 and 130,

consisting of a portion of the SEQUENCE LISTING containing SEQ ID NOS: 69-77 should be deleted and the attached new sheet containing SEQ ID NOS: 69-77 should be inserted therefor.

Columns 149 and 150,

consisting of a portion of the SEQUENCE LISTING containing SEQ ID NO: 116 should be deleted and the attached new sheet containing SEQ ID NO: 116 should be inserted therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number

Leona L. Lauder  
235 Montgomery Street, Suite 1026  
San Francisco, CA 94104-3008

PATENT NO. 7,115,715 B2

No. of additional copies



1

SEP 18 2006

-continued

---

<213> ORGANISM: HUMAN

<400> SEQUENCE: 69  
cagtcgtgag g

11

<210> SEQ ID NO 70  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 70  
ccgaggtgag c

11

<210> SEQ ID NO 71  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 71  
tggaggtacc a

11

<210> SEQ ID NO 72  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 72  
ggaaggtcag t

11

<210> SEQ ID NO 73  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 73  
agcaggtggg c

11

<210> SEQ ID NO 74  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 74  
gccaggtaca g

11

<210> SEQ ID NO 75  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 75  
tgctggtgag t

11

<210> SEQ ID NO 76  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 76  
cacaggtatt a

11

<210> SEQ ID NO 77  
<211> LENGTH: 11

DEC 18 2006

-continued

&lt;400&gt; 116

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
 1 5 10 15

The invention claimed is:

1. An anti-idiotypic antibody to an idiotype of a second antibody, wherein said idiotype of said second antibody specifically binds to an epitope of MN protein, wherein said anti-idiotypic antibody comprises an internal image corresponding to said epitope of said MN protein, and wherein said MN protein has an amino acid sequence of SEQ ID NO: 2 that is encoded by a nucleic acid selected from the group consisting of:

- (a) SEQ ID NO: 1; and
- (b) polynucleotides that differ from SEQ ID NO: 1 due to the degeneracy of the genetic code.

2. An anti-idiotypic antibody according to claim 1, wherein said second antibody that is specific for said epitope of the MN protein, is either the M75 monoclonal antibody secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, or the MN12 monoclonal antibody that is secreted from the hybridoma MN 12.2.2, which was deposited at the American Type Culture Collection under ATCC No. HB 1647.

3. The anti-idiotypic antibody according to claim 1 where said second antibody is an antigen-binding antibody fragment.

\* \* \* \* \*

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO. : 7,115,715 B2

DATED : October 3, 2006

INVENTOR(S) : Jan Zavada et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 23, Table 1,

Line 52, "Intron" should read -- Exon --.

Column 24,

Line 19, "Rnase" should read -- RNase --.

Columns 129 and 130,

consisting of a portion of the SEQUENCE LISTING containing SEQ ID NOS: 69-77 should be deleted and the attached new sheet containing SEQ ID NOS: 69-77 should be inserted therefor.

Columns 149 and 150,

consisting of a portion of the SEQUENCE LISTING containing SEQ ID NO: 116 should be deleted and the attached new sheet containing SEQ ID NO: 116 should be inserted therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number

Leona L. Lauder  
235 Montgomery Street, Suite 1026  
San Francisco, CA 94104-3008

PATENT NO. 7,115,715 B2

No. of additional copies

→ 1

1 8 2006



-continued

---

<213> ORGANISM: HUMAN

<400> SEQUENCE: 69  
cagtcgtgag g

11

<210> SEQ ID NO 70  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 70  
ccgaggtgag c

11

<210> SEQ ID NO 71  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 71  
tggaggtacc a

11

<210> SEQ ID NO 72  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 72  
ggaaggtcag t

11

<210> SEQ ID NO 73  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 73  
agcaggtggg c

11

<210> SEQ ID NO 74  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 74  
gccaggtaca g

11

<210> SEQ ID NO 75  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 75  
tgctggtgag t

11

<210> SEQ ID NO 76  
<211> LENGTH: 11  
<212> TYPE: DNA  
<213> ORGANISM: HUMAN

<400> SEQUENCE: 76  
cacaggtatt a

11

<210> SEQ ID NO 77  
<211> LENGTH: 11

DEC 18 2006

-continued

&lt;400&gt; 116

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
 1 5 10 15

The invention claimed is:

1. An anti-idiotypic antibody to an idiotype of a second antibody, wherein said idiotype of said second antibody specifically binds to an epitope of MN protein, wherein said anti-idiotypic antibody comprises an internal image corresponding to said epitope of said MN protein, and wherein said MN protein has an amino acid sequence of SEQ ID NO: 2 that is encoded by a nucleic acid selected from the group consisting of:

(a) SEQ ID NO: 1; and

(b) polynucleotides that differ from SEQ ID NO: 1 due to the degeneracy of the genetic code.

2. An anti-idiotypic antibody according to claim 1, wherein said second antibody that is specific for said epitope of the MN protein, is either the M75 monoclonal antibody secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, or the MN12 monoclonal antibody that is secreted from the hybridoma MN 12.2.2, which was deposited at the American Type Culture Collection under ATCC No. HB 1647.

3. The anti-idiotypic antibody according to claim 1 where said second antibody is an antigen-binding antibody fragment.

\* \* \* \* \*

DEC 18 2005